Breaking News
February 20, 2018 - Lab-grown cerebellar cells may help explain how ASD develops at molecular level
February 20, 2018 - New Treatment Apalutamide (Erleada) Approved for Prostate Cancer That Resists Hormone Therapy
February 20, 2018 - Do You Really Need My Signature on That?
February 20, 2018 - HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection
February 20, 2018 - Diabetes does not increase work-loss years due to early retirement
February 20, 2018 - Researchers aim to find out how PTSD affects decisions of police
February 20, 2018 - UH Cleveland Medical Center explores novel treatments for uterine fibroids
February 20, 2018 - Flu Vax Efficacy 25% Against Predominant H3N2 Strain So Far
February 20, 2018 - HIV screening most optimal at 25 years of age if no risk factors
February 20, 2018 - Loyola Medicine primary care physician offers advice to minimize risk of flu
February 20, 2018 - Safe sleep recommendations for parents that may help reduce child’s risk of SUID
February 20, 2018 - Why Do So Few Docs Have Buprenorphine Waivers?
February 20, 2018 - Low levels of alcohol good for the brain
February 20, 2018 - Experimental treatment improves invisible symptoms of a man with spinal cord injury
February 20, 2018 - Myriad’s EndoPredict offers better prediction of breast cancer recurrence, analysis shows
February 20, 2018 - Researchers identify fifteen genes that determine our facial features
February 20, 2018 - Morning Break: New Health IT Player; Luxturna No Bargain; Nuclear Freakout
February 20, 2018 - How does it compare? Hospice care at home, at assisted living facility, at nursing home
February 19, 2018 - Scientists develop water-soluble warped nanographene for bioimaging
February 19, 2018 - It’s Not Your Imagination: You’re Hungrier After Losing Weight
February 19, 2018 - Antihypertensive Use At Delivery Rising in Preeclampsia
February 19, 2018 - A centuries-old math equation used to solve a modern-day genetics challenge
February 19, 2018 - Liquid biopsies could be used as new predictive marker for metastatic TNBC
February 19, 2018 - Russian researchers develop new multi-layered biodegradable scaffolds
February 19, 2018 - Are ‘Vaccine Skeptics’ Responsible for Flu Deaths?
February 19, 2018 - Hidden genetic effects behind immune diseases may be missed, study suggests
February 19, 2018 - Emergency nurses experience regular verbal and physical abuse
February 19, 2018 - Study sheds light on biology that guides behavior across different stages of life
February 19, 2018 - Morning Break: Transgender Breast Feeding; Brazilian ‘Pro-Vaxxers’; Post-Stroke Exercise
February 19, 2018 - Meningitis vaccination strategy in Africa found to be effective, economical
February 19, 2018 - Researchers uncover how excess calcium may influence development of Parkinson’s disease
February 19, 2018 - Psoriasis drug also effective at reducing aortic inflammation
February 19, 2018 - Excess emissions can make serious contributions to air pollution, study shows
February 19, 2018 - Researchers reveal potential biological roots behind individuality
February 19, 2018 - Diabetes Drugs Differ on HF; School-Based Obesity Program Flop; Plaque Type in ACS
February 19, 2018 - Surgical infections linked to drug-resistant bugs, study suggests
February 19, 2018 - Poor awareness may hinder a child’s early dental care
February 19, 2018 - Research finds rising trend in incidence of merkel cell carcinoma
February 19, 2018 - Researchers uncover Ras protein’s role in uncontrolled cancer growth
February 19, 2018 - FDA Approves Apalutamide (Erleada) to Help Curb a Tough-to-Treat Prostate Cancer
February 19, 2018 - Educational Tool Boosts Cervical Length Screening
February 19, 2018 - Spider’s web inspires removable implant that may control type 1 diabetes
February 19, 2018 - Scientists develop fluorescent probe to identify cancer stem cells
February 19, 2018 - University Hospital of Santiago de Compostela participates in large pancreatic cancer study
February 19, 2018 - New blood test shows promise to revolutionize diagnosis of tick-borne diseases
February 19, 2018 - Report: Use, Not Price, Drives State Health Costs
February 19, 2018 - Emergency services crews often unprepared for diabetic crises
February 19, 2018 - Scientists in Sweden create DNA nanowires that offer hope for treatment of diseases
February 19, 2018 - ID Break: Clean Hands, Fewer Abx; $11 Million HIV Cure?; MenB Vax for Kids
February 19, 2018 - Patient exposure to X-rays depends on how dentists are paid
February 19, 2018 - Study reveals parents’ views toward children’s tanning bed use
February 19, 2018 - Shot may help reduce risk of shingles
February 19, 2018 - FDA approves first treatment to reduce risk of NSCLC progression
February 19, 2018 - FDA Expands Approval of Imfinzi (durvalumab) to Reduce the Risk of Non-Small Cell Lung Cancer Progressing
February 19, 2018 - D.C. Week: Congress Passes Spending Bill
February 19, 2018 - Heart-muscle patches made with human cells improve heart attack recovery
February 19, 2018 - FDA Approves First Blood Test to Detect Concussions
February 19, 2018 - Survival Bump in Bladder Cancer with Keytruda
February 18, 2018 - Scientists describe the mechanism of heart regeneration in the zebrafish
February 18, 2018 - Scientists uncover the structure of microtubule motor proteins
February 18, 2018 - Light-activated cancer drugs without toxic side effects are closer to becoming reality
February 18, 2018 - Pioneering research could provide novel insight into how genomic information is read
February 18, 2018 - Pearls From: David Putrino, PhD
February 18, 2018 - Researchers uncover how cancer stem cells drive triple-negative breast cancer
February 18, 2018 - Morning Break: Anti-Anti-Vaxxers; Private Piercings Prohibited; A Case for Pelvic Massage
February 18, 2018 - Lower-dose radiation effective, safe for HPV+ head and neck cancer after induction chemo
February 18, 2018 - Specialist residential service for adults with autism opens in Swansea
February 18, 2018 - FDA Moves to Limit Loperamide Doses per Package
February 18, 2018 - Alcohol use disorder – Genetics Home Reference
February 18, 2018 - Autism might be better detected using new two-minute questionnaire
February 18, 2018 - Hand hygiene-intervention practices may reduce risk of infection among nursing home patients
February 18, 2018 - Researchers develop most sophisticated mini-livers to date
February 18, 2018 - Obamacare Helped More Young Women Get Prenatal Care: Study
February 18, 2018 - School-Based Program Fails to Dent Kids’ Obesity
February 18, 2018 - Research compares neural activity in children with and without autism spectrum disorder
February 18, 2018 - Poor fitness levels increase the risk dementia, concludes study
February 18, 2018 - Risk Score May Reveal if Kids are Victims of Ill-Treatment
February 18, 2018 - Adding Folic Acid to Corn Masa Flour May Prevent Birth Defects
February 18, 2018 - Acute treatment suppresses posttraumatic arthritis in ankle injury
February 18, 2018 - A Role for Budesonide in Autoimmune Hepatitis?
Rapid Onset Seen for Apremilast in PsA

Rapid Onset Seen for Apremilast in PsA

image_pdfDownload PDFimage_print

Action Points

  • Note that this randomized trial demonstrated that apremilast was efficacious in improving psoriatic arthritis symptoms in biologically naive patients.
  • The fact that apremilast, a phosphodiesterase inhibitor, is an oral agent may lead to broader adoption over IV agents.

Monotherapy with apremilast (Otezla) among patients with psoriatic arthritis who were biologic-naive was significantly more effective than placebo as early as week 2 in a phase IIIb study.

After the second week of treatment, 16.4% of patients randomized to apremilast had achieved a 20% improvement on the criteria of the American College of Rheumatology (ACR20) compared with 6.4% of those receiving placebo (P=0.025), reported Peter Nash, MD, of the University of Queensland in Brisbane, Australia, and colleagues.

A statistically significant difference on ACR20 response rates also was seen between the apremilast and placebo groups at week 16, which was the study’s primary endpoint (38.2% versus 20.2%, P=0.004), the researchers reported online in Annals of the Rheumatic Diseases.

The efficacy of the phosphodiesterase 4 inhibitor apremilast among patients with psoriatic arthritis who had previous exposure to conventional disease-modifying anti-rheumatic drugs (DMARDs) and/or biologic agents was demonstrated in the three PALACE trials that were part of the drug’s clinical trial development program, with follow-up of up to 4 years. Concomitant conventional DMARD therapy was permitted in these trials.

The time to onset of the effect has not previously been assessed, however, and only one trial evaluated monotherapy.

Therefore, Nash and colleagues enrolled 219 patients who had previously received one conventional DMARD but no biologics in the study, named ACTIVE, assessing time to response and various other outcomes including effects on morning stiffness and enthesitis.

Patients had active psoriatic arthritis for at least 3 months, with three or more tender and swollen joints and C-reactive protein levels of 0.2 mg/dL or higher. Patients had to discontinue DMARDs but were allowed oral prednisone in dosages of 10 mg/day or less as well as nonsteroidal anti-inflammatory drugs or opioids.

Participants’ mean age was 49, and more than half were women. Almost all were white. The mean disease duration was 3.8 years; the mean number of swollen and tender joints were 10 and 18, respectively; and mean body mass index was 32 kg/m2.

Patients were randomized to receive oral apremilast, 30 mg twice daily, or placebo for the first 24 weeks. At week 16, those who had not had at least a 10% improvement in tender and joint counts were allowed early escape, and at week 24, all those still on placebo were switched to apremilast for the remainder of the 52-week study.

At week 2 — the first post-baseline assessment — significant mean changes from baseline other than ACR20 rates were seen on these outcomes for apremilast versus placebo:

  • Disease Activity Score in 28 joints (DAS28), -0.59 versus -0.31, P<0.05
  • Gladman Enthesitis Index, -1.1 versus -0.4, P<0.05
  • Health Assessment Questionnaire Disability Index (HAQl-DI), -0.13 versus -0.05, P<0.05

In addition, improvements in the severity of morning stiffness were reported at that time point for 42.7% versus 21.1% (P<0.005).

At week 16, significant percentage improvements were seen for swollen joints (-46.4% versus 4.2%, P<0.0001) and tender joints (-32.3% versus 2.5%, P<0.005), as well as in the duration of morning stiffness (-33.33 minutes versus no change, P<0.005).

Functional ability assessed on the HAQ-DI showed “clinically meaningful and significant improvements” at week 16 for apremilast versus placebo (-0.21 versus -0.06, P=0.023), and the mean changes in HAQ-DI scores met the minimal clinically important difference of -0.13 at weeks 2, 16, and 24.

Clinical benefits were sustained in the open-label phase through week 52 with apremilast treatment, at which time the percentage changes in swollen and tender joint counts were -77.5% and -70.4%, respectively.

During the blinded phase of the study, the most common adverse events were diarrhea, seen in 14.7% of the apremilast group and 11% of the placebo group, nasopharyngitis, nausea, and headache. Ten patients receiving apremilast and five on placebo discontinued during the first 24 weeks because of adverse events. Serious adverse events, none of which were considered treatment-related, were reported in 2.8% of the apremilast group and 4.6% of the placebo group during the blinded phase of the trial.

Four patients reported depression, but none were serious, and there were no cases of suicidal behavior or ideation, Nash and colleagues said.

Study limitations, they noted, included the fact that there was some baseline patient heterogeneity and there was a lack of imaging outcomes.

“Apremilast has a unique mechanism of action in modulating the expression of both pro-inflammatory and anti-inflammatory cytokines; in ACTIVE, no evidence of increased incidence of serious or opportunistic infections and no cases of active tuberculosis with 52-week apremilast exposure were observed,” the researchers said.

“These results support the use of apremilast monotherapy in biological-naive patients with psoriatic arthritis.”

The study was sponsored by Celgene Corporation.

The authors reported financial relationships with Celgene, Novartis, Roche, Schering-Plough, Bristol-Myers Squibb, Pfizer, UCB, AbbVie, Ardea Biosciences, AstraZeneca, Centocor, Galapagos, Genentech, GlaxoSmithKline, Human Genome Sciences, Janssen, Eli Lilly, Merck, Mesoblast, Novartis, Novo Nordisk, Sanofi-Aventis, Takeda, and Vertex Pharmaceuticals. Several co-authors are employees of Celgene.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-01-19T12:30:00-0500

Tagged with:

About author

Related Articles